Observational studyJapanese journal of clinical oncology2025
Real-world safety and effectiveness of alemtuzumab for relapsed or refractory chronic lymphocytic leukaemia: results from postmarketing surveillance in Japan.
Yukie Sasakura et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.